DRD Biotech develops rapid blood tests utilizing biomarker detection of NR2 antibodies to diagnose ischemic stroke and traumatic brain injury. Their technology provides timely and accurate assessments of brain damage, enabling healthcare providers to make informed decisions quickly.
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current diagnostic methods for ischemic stroke and traumatic brain injury often lack the speed and accessibility needed for timely intervention. Delays in accurate diagnosis can lead to worsened patient outcomes and limit the effectiveness of treatment options.
Solution
DRD Biotech is developing rapid blood tests for the diagnosis of ischemic stroke and traumatic brain injury, based on the detection of NR2 antibodies, a biomarker of cerebral ischemia. These tests aim to provide a fast and accurate assessment of brain damage at the point of care, enabling healthcare providers to make more informed and timely treatment decisions. By measuring the concentration of NR2 antibodies in the blood, the tests can identify patients at increased risk of ischemic stroke and other brain injuries. The company's focus is on creating affordable and accessible diagnostic tools that improve patient outcomes in critical care settings.
Target Audience
The primary target audience includes emergency room physicians, neurologists, and other healthcare providers involved in the diagnosis and treatment of stroke and traumatic brain injury patients.
Features
- Rapid blood test format for point-of-care use
- Detects NR2 antibodies, a biomarker specific to cerebral ischemia
- Quantitative measurement of NR2 antibody concentration in blood
- Results available in minutes, enabling rapid decision-making
- Designed for use in both laboratory and point-of-care settings